Form 8-K - Current report:
SEC Accession No. 0001641172-25-015355
Filing Date
2025-06-17
Accepted
2025-06-17 10:32:42
Documents
23
Period of Report
2025-06-17
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K form8-k.htm   iXBRL 8-K 43569
2 EX-10.1 ex10-1.htm EX-10.1 9255
3 EX-99.1 ex99-1.htm EX-99.1 16786
4 GRAPHIC ex10-1_001.jpg GRAPHIC 1125897
5 GRAPHIC ex10-1_002.jpg GRAPHIC 1070954
6 GRAPHIC ex10-1_003.jpg GRAPHIC 1034802
7 GRAPHIC ex10-1_004.jpg GRAPHIC 1079460
8 GRAPHIC ex10-1_005.jpg GRAPHIC 1121286
9 GRAPHIC ex10-1_006.jpg GRAPHIC 1145694
10 GRAPHIC ex10-1_007.jpg GRAPHIC 823803
11 GRAPHIC ex10-1_008.jpg GRAPHIC 348394
12 GRAPHIC ex10-1_009.jpg GRAPHIC 591396
  Complete submission text file 0001641172-25-015355.txt   11728015

Data Files

Seq Description Document Type Size
13 XBRL SCHEMA FILE pcsa-20250617.xsd EX-101.SCH 3059
14 XBRL LABEL FILE pcsa-20250617_lab.xml EX-101.LAB 34239
15 XBRL PRESENTATION FILE pcsa-20250617_pre.xml EX-101.PRE 22388
25 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3698
Mailing Address 7380 COCA COLA DRIVE SUITE 106 HANOVER MD 21076
Business Address 7380 COCA COLA DRIVE SUITE 106 HANOVER MD 21076 443-776-3133
Processa Pharmaceuticals, Inc. (Filer) CIK: 0001533743 (see all company filings)

EIN.: 451539785 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39531 | Film No.: 251052224
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)